Coloplast completes the acquisition of Kerecis

Coloplast has completed the acquisition of Kerecis, announced on July 7, 2023, after receiving approval from all relevant authorities and reaching a shareholder acceptance level of 100%

The terms of the transaction and the financial assumptions stated in Coloplast's stock exchange announcement no. 03/2023 regarding the acquisition of Kerecis are unchanged. The equity capital raise related to the financing of the acquisition was completed on August 30, 2023.

Kerecis will be included in the financials for FY 2022/23 with 1 month of impact. Revenue contribution will be included as acquired growth under the existing Wound and Skin Care business area, which will be renamed to Advanced Wound Care. The financial guidance for FY 2022/23 as described in the Interim Financial Report for 9M 2022/23 (announcement no. 04/2023) is unchanged.

Kerecis – an emerging category leader in the US-centric biologics wound care segment

Kerecis is an innovative, fast-growing company in the biologics wound care segment with a strong commercial presence in the US. The company has developed and patented a clinically differentiated technology based on intact fish skin. The fish-skin technology is minimally processed, sustainable, and scalable. Backed by compelling clinical evidence, the technology has already been used to treat tens of thousands of patients.

With the acquisition of Kerecis, Coloplast obtains a long-term growth business with strong profitability expansion potential, well-positioned for long-term value creation.

“I am very excited to welcome the Kerecis team into the Coloplast family. Both Coloplast and Kerecis are on a mission to help many more patients in need of advanced wound treatment, and I look forward to continuing the growth and profitability journey, as we build a truly global wound care franchise together” says Kristian Villumsen, President & CEO of Coloplast and continues: “On September 4, we will host a conference call where investors and analysts will get an opportunity to meet Fertram Sigurjonsson, founder and CEO of Kerecis. Fertram is an outstanding leader, and I am impressed by the strong results that he and his team have created. The success of Kerecis is a testament to both the strength of its unique fish-skin technology, as well as strong commercial execution, enabled by a highly motivated and purpose-driven organisation” says Kristian.